Post hoc subgroups in clinical trials: Anathema or analytics?

Clinical Trials

Volumn 12, Issue 4, 2015, Pages 357-364

  Weisberg, Herbert I ^a   Pontes, Victor P ^a  

^a Johnson and Johnson Regenerative Therapeutics   (United States)

Author keywords

Adaptive signature; Cadit; Highly Accurate and Robust Variable Evaluation Selection and Testing; Personalized medicine; Precision medicine; Predictive analytics; Randomized Aldactone Evaluation Study; Spironolactone; Subgroups

Indexed keywords

SPIRONOLACTONE; DIURETIC AGENT;

ALGORITHM; CADIT MODELING; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DATA MINING; DECISION TREE; DRUG DOSE REDUCTION; HEART FAILURE; HUMAN; HYPERKALEMIA; PERSONALIZED MEDICINE; POST HOC ANALYSIS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VARIABLE SELECTION ALGORITHM; FEMALE; FORECASTING; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ALGORITHMS; DATA INTERPRETATION, STATISTICAL; DIURETICS; FEMALE; FORECASTING; HEART FAILURE; HUMANS; MALE; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84943261253     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774515588096     Document Type: Conference Paper

References (16)

1. Lo VS. The true lift model. ACM SIGKDD Explor Newsl 2002; 4: 78-86.
2. Radcliffe NJ. Using control groups to target on predicted lift: building and assessing uplift models. Direct Market Anal J 2007; 14-21.
3. Weisberg HI. Bias and causation: models and judgment for valid comparisons. Hoboken, NJ: John Wiley & Sons, 2010.
4. Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008; 14: 5984-5993.
5. Radcliffe NJ and Surry PD. Real-world uplift modelling with significance-based uplift trees. Boston, MA: Portrait Software, 2011.
6. Rzepakowski P and Jaroszewicz S. Decision trees for uplift modeling. In: Proceedings of the IEEE conference on data mining, Sydney, NSW, Australia, 13-17 December 2010, pp. 441-450. New York: IEEE.
7. Breiman L, Friedman J, Olshen RA, et al. Classification and regression trees. New York: Chapman & Hall, 1984.
8. Jaskowski M and Jaroszewicz S. Uplift modeling for clinical trial data. In: IEEE workshop on machine learning for clinical data analysis, Edinburgh, Scotland, 2012.
9. Weisberg HI and Pontes VP. Estimation of individual causal effects. Patent 8,688,610 B1, USA, granted 1 April 2014.
10. Signorovitch JE. Identifying informative biological markers in high-dimensional genomic data and clinical trials. Ph.D. Thesis, Department of Biostatistics, Harvard University School of Public Health, 2007.
11. Tian L, Ash AA, Gentles AJ, et al. A simple method for estimating interactions between a treatment and a large number of covariates. J Am Stat Assoc 2014; 109: 1517-1532.
12. Harrell FE Jr. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer, 2001.
13. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
14. Juurlink DM, Mamdani M, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 543-551.
15. Freidlin B and Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005; 11: 7872-7878.
16. Freidlin B, Jiang W and Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010; 16: 691-698.